Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fianlimab - Regeneron Pharmaceuticals

Next Previous
X
Search
Drug Profile

Fianlimab - Regeneron Pharmaceuticals

Alternative Names: Anti-LAG-3 antibody - Regeneron Pharmaceuticals; REGN-3767

Latest Information Update: 29 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase II/III Non-small cell lung cancer
  • Phase II Solid tumours
  • Phase I Haematological malignancies

Most Recent Events

  • 26 Aug 2024 Columbia University plans a phase II trial for Bladder cancer (Combination therapy) in USA (IV) (NCT06571708)
  • 21 Aug 2024 Phase I development is ongoing for Haematological malignancies (Late-stage disease, Combination therapy) in Australia, Ireland, South Korea, United Kingdom, USA (IV) (Regeneron pipeline, May 2024)
  • 19 Aug 2024 Phase-III clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, First-line therapy) in USA (IV) (NCT06246916)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top